Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
The role of cannabis in cognitive functioning of patients with schizophrenia
- T. Schnell, D. Koethe, J. Daumann, E. Gouzoulis-Mayfrank
- Medicine, Psychology
- Psychopharmacology
- 27 March 2009
RationaleCognitive deficits are commonly found both in patients with schizophrenia (SCH) and in people with cannabis use disorders (CUD). Surprisingly, some small recent studies reported better… Expand
Memory impairment suggests hippocampal dysfunction in abstinent ecstasy users
- E. Gouzoulis-Mayfrank, B. Thimm, Markus Rezk, G. Hensen, J. Daumann
- Psychology, Medicine
- Progress in Neuro-Psychopharmacology and…
- 1 August 2003
Previous studies have consistently shown impairments of memory and learning in regular users of the neurotoxic drug ecstasy (3,4-methylenedioxymethamphetamine [MDMA]). In addition, deficits in… Expand
Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
- E. Gouzoulis-Mayfrank, K. Heekeren, +4 authors K. Kovar
- Psychology, Medicine
- Pharmacopsychiatry
- 1 November 2005
INTRODUCTION
Pharmacological challenges with hallucinogens are used as models for psychosis in experimental research. The state induced by glutamate antagonists such as phencyclidine (PCP) is often… Expand
Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers
Results of an experimental double-blind…
- E. Gouzoulis-Mayfrank, B. Thelen, +6 authors H. Sass
- Psychology, Medicine
- Psychopharmacology
- 1 February 1999
Abstract The aim of this study was to contribute to the characterization of the entactogen (ecstasy) substance group. The psychopathological, neuroendocrine and autonomic effects of common… Expand
Neurometabolic Effects of Psilocybin, 3,4-Methylenedioxyethylamphetamine (MDE) and d-Methamphetamine in Healthy Volunteers A Double-Blind, Placebo-Controlled PET Study with [18F]FDG
- E. Gouzoulis-Mayfrank, M. Schreckenberger, +7 authors H. Sass
- Psychology, Medicine
- Neuropsychopharmacology
- 1 June 1999
The neurometabolic effects of the hallucinogen psilocybin (PSI; 0.2 mg/kg), the entactogen 3,4-methylenedioxyethylamphetamine (MDE; 2 mg/kg) and the stimulant d-methamphetamine (METH; 0.2–0.4 mg/kg)… Expand
High Intensity Dependence of Auditory Evoked Dipole Source Activity Indicates Decreased Serotonergic Activity in Abstinent Ecstasy (MDMA) Users
- F. Tuchtenhagen, J. Daumann, +6 authors E. Gouzoulis-Mayfrank
- Psychology, Medicine
- Neuropsychopharmacology
- 1 June 2000
Neurotoxic damage of central serotonergic systems has been demonstrated in numerous animal studies after exposure to methylenedioxyamphetamines (ecstasy). A high intensity dependence of auditory… Expand
Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal…
- J. Daumann, G. Hensen, B. Thimm, Markus Rezk, Bianca Till, E. Gouzoulis-Mayfrank
- Psychology, Medicine
- Psychopharmacology
- 14 January 2004
Rationale3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) has become a widely used recreational drug among young people. This is of great concern, since MDMA is neurotoxic in animal studies and its… Expand
Cerebral activation in abstinent ecstasy (MDMA) users during a working memory task: a functional magnetic resonance imaging (fMRI) study.
- J. Daumann, B. Fimm, K. Willmes, A. Thron, E. Gouzoulis-Mayfrank
- Psychology, Medicine
- Brain research. Cognitive brain research
- 1 May 2003
The popular recreational drug ecstasy (3,4-methylenedioxymethamphetamine=MDMA and related congeners) is neurotoxic upon central serotonergic systems in animal studies. So far, the most convincing… Expand
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
- E. Gouzoulis-Mayfrank, J. Daumann, +5 authors H. Sass
- Psychology, Medicine
- Journal of neurology, neurosurgery, and…
- 1 June 2000
OBJECTIVES
Ecstasy (3,4-methylenedioxymethamphetamine (MDMA) and related congerers: MDA, MDEA) is the name given to a group of popular recreational drugs. Animal data raise concern about neurotoxic… Expand
Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis
- K. Heekeren, J. Daumann, +5 authors E. Gouzoulis-Mayfrank
- Psychology, Medicine
- Psychopharmacology
- 18 May 2008
RationaleMany studies have reported deficits of mismatch negativity (MMN) in schizophrenic patients. Pharmacological challenges with hallucinogens in healthy humans are used as models for psychotic… Expand